Skip to main content

Table 1 Baseline clinicopathological characteristics of patients with PTC

From: Clinical and prognosis value of the number of metastatic lymph nodes in patients with papillary thyroid carcinoma

Variates

Value

Cases of patients

1453

Age, median (range)

44.8 ± 11.9, 46 (15–88)

Sex, male/female, number (%)

368/1085 (25.3/74.7)

Primary tumor size, median (mm)

11.1 ± 7.2, 8.0 (0.1–55.0)

PTMC/non-PTMC, number (%)

863/590 (59.4/40.6)

LN involvement, pN0/ pN1a/ pN1b, number (%)

581/698/174 (40.0/48.0/12.0)

total checked number of LNs ≥ 5/ < 5 among pN1patients

694/178(79.6/20.4)

NMLNs among pN1patients with a total checked number of LNs ≥ 5, NMLNs ≤ 5/ NMLNs > 5, number (%)

472/222 (68.0/32.0)

CLNs among pN1patients with a total checked number of LNs ≥ 5, CLNs ≤ 5/ > 5, number (%)

535/159 (75.7/24.3)

LLNs among pN1patients with a total checked number of LNs ≥ 5, LLNs ≤ 5/ > 5, number (%)

624/70(89.9/10.1)

Bilaterality, number (%)

407 (28.0)

Multifocality, number (%)

531 (36.5)

ETE /without ETE, number (%)

1046/407 (72.0/28.0)

TNM stage, I/II, number (%)

1304/149 (89.7%/10.3%)

BRAFV600E mutation, positive/negative/unknown, number (%)

143/30/1280 (9.8/2.1/88.1)

HT, number (%)

196 (13.5)

Duration of follow up (months)

4–42 (22)

  1. NMLNs number of metastatic lymph nodes, CLNs number of central cervical lymph nodes metastasis, LLNs number of lateral lymph nodes metastasis, ETE extrathyroidal extension, TNM stage tumor node metastasis stage, HT Hashimoto’s thyroiditis